| Document |
Document Title |
|
WO/2018/043400A1 |
A compound represented by formula (I) or a salt thereof. In formula (I), each of R1 and R4 independently represents a hydrogen atom, an unsubstituted or substituted C1-6 alkyl group or the like; R2 represents a hydrogen atom, an unsubsti...
|
|
WO/2018/044783A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2018/045149A1 |
Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is -OH or -OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists ...
|
|
WO/2018/035296A1 |
Kinases can be engineered to utilize an ATP analog that is not readily utilized by wild-type kinases by introducing a mutation in the ATP-binding pocket. However, application of this method has been limited by the membrane impermeability...
|
|
WO/2018/034216A1 |
Provided are a compound, a composition, a cured object, an optically anisotropic body, and a reflective film that have a high refractive index anisotropy Δn and excellent light resistant properties, and that exhibit liquid crystallinity...
|
|
WO/2018/029150A1 |
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...
|
|
WO/2018/031707A1 |
Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for ...
|
|
WO/2018/028557A1 |
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of 1-phosphate sphingosine 1 subtype (S1P1), and in particular to the compounds shown in formula (I), and tautomers or pharmaceutic...
|
|
WO/2018/024188A1 |
Provided are a polycyclic compound and a manufacturing method, pharmaceutical composition, and application thereof. The structure of the polycyclic compound and an isomer, prodrug, solvate, hydrate, stable isotopic derivative, or pharmac...
|
|
WO/2018/021818A1 |
The present invention relates to a method for producing high-purity crystalline febuxostat, high-purity crystalline febuxostat produced by the method, and a pharmaceutical composition comprising the febuxostat as an active ingredient. Th...
|
|
WO/2018/023130A1 |
Triazabutadiene molecules as cleavable cross-linkers adapted to cross-link components with click chemistry, e.g., clickable triazabutadienes. For example, in some embodiments, the triazabutadienes feature alkyne handles attached to the i...
|
|
WO/2018/019291A1 |
Provided is a method of synthesizing a C(sp3)-C(sp2) cross-coupled compound comprising reacting a C(sp3) coupling partner with a C(sp2) coupling partner, a catalyst, and a solvent; wherein the C(sp3) coupling partner comprises an organic...
|
|
WO/2018/018091A1 |
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
|
|
WO/2018/013508A1 |
Described herein are substituted aminothiazoles, compositions comprising same; and methods of making and using same.
|
|
WO/2018/011747A1 |
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...
|
|
WO/2018/008989A1 |
The present invention provides a benzo[d]thiazole derivative or a pharmaceutically acceptable salt thereof, a method for producing the same, and a pharmaceutical composition including the same. The benzo[d]thiazole derivative or the phar...
|
|
WO/2018/005416A1 |
A dual curable thiol-ene composition comprising a polythiol, an unsaturated compound, a photoinitiator, an organic hydroperoxide (thermal initiator) and optionally a nitrogen-containing base, such as e.g. an N-heterocyclic compound (toge...
|
|
WO/2017/219083A1 |
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...
|
|
WO/2017/223491A1 |
Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin ...
|
|
WO/2017/215552A1 |
Compounds, pharmaceutical compositions, and methods for treatment of microbial infections are provided. The compounds can potentiate the therapeutic effects of one or more antimicrobial agents when co-administered. The compounds have ant...
|
|
WO/2017/214005A1 |
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicament.
|
|
WO/2017/206955A1 |
Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection. Specifically, provided are applications of a compound represented by formula (I) and a pharmaceu...
|
|
WO/2017/210696A1 |
Embodiments relate to pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder, prostate disorders and met...
|
|
WO/2017/207362A1 |
Compounds of the formula (I): wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.
|
|
WO/2017/202376A1 |
A sulfamide compound and a use thereof in preparing pain killers, which specifically relates to compounds as shown in formula (I) and formula (II), tautomers thereof or pharmaceutically acceptable salts thereof.
|
|
WO/2017/198647A1 |
The invention relates to antibacterial compounds of formula (I) wherein the group M and R1 are as defined in the claims, and salts thereof.
|
|
WO/2017/199862A1 |
The purpose of the present invention is to provide a method for manufacturing a high-purity polymerizable compound in an industrially advantageous manner. The manufacturing method according to the present invention is a method for manufa...
|
|
WO/2017/198178A1 |
A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula ...
|
|
WO/2017/201502A1 |
Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceut...
|
|
WO/2017/201501A1 |
Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceut...
|
|
WO/2017/193757A1 |
Provided are a water-soluble Epothilone derivative represented by formula (I), a preparation method therefor and an intermediate thereof, and an application thereof in preparation of drugs for inhibiting growth of tumor cells.
|
|
WO/2017/193041A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2017/193063A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2017/188485A1 |
Provided is a compound represented by formula (A-V), wherein Y represents a p-valent anion; R1A to R8A each independently represent a hydrogen atom or an alkyl group having 1-10 carbon atoms; R9A and R10A each independently represent a h...
|
|
WO/2017/184624A1 |
In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) ...
|
|
WO/2017/181585A1 |
The present invention relates to the technical field of medicine, and specifically relates to a PUMA inhibitor, a method for preparation thereof, and a use thereof. The PUMA inhibitor is the compound as shown in (I) or a pharmaceutically...
|
|
WO/2017/184604A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2017/183625A1 |
[Problem] To provide an organic electroluminescence element comprising, in order to improve the element characteristics of the organic EL element, in particular, so as to absorb 400-410 nm wavelength sunlight and not have effects on an i...
|
|
WO/2017/183723A1 |
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...
|
|
WO/2017/178174A1 |
The present invention relates compounds useful and their use for treating cholestatic and fibrotic diseases.
|
|
WO/2017/179883A1 |
The present specification relates to a compound expressed by the first chemical formula, and to an organic electronic element comprising same.
|
|
WO/2017/175986A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure provides an organic electroluminesce...
|
|
WO/2017/174640A1 |
The invention relates to novel compounds of the Formula (I), to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
|
|
WO/2017/169839A1 |
The present invention provides a novel method for producing a 2-hydrazinobenzothiazole derivative. The present invention also provides: a method for producing a compound using the 2-hydrazinobenzothiazole derivative obtained by said prod...
|
|
WO/2017/173313A1 |
Pateamine A derivatives, pharmaceutical compositions that include the derivatives, and methods for treating chronic lymphocytic leukemia using the derivatives.
|
|
WO/2017/165204A1 |
Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also desc...
|
|
WO/2017/165256A1 |
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...
|
|
WO/2017/161524A1 |
Provided is a pyruvate dehydrogenase kinase inhibitor and an application therefor. Specifically provided is a compound Ra-S-S-Rb of formula X or a pharmaceutically acceptable salt thereof, the compound having excellent inhibition of pyru...
|
|
WO/2017/160922A1 |
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.
|
|
WO/2017/161183A1 |
There are provided, inter alia, compositions and methods for covalently binding peptides to proteins.
|
